Indications for FibroScan in Chronic Liver Disease

Primary Clinical Indications by Disease Category

• The European Association for the Study of the Liver (EASL) recommends calculating FIB-4 score first using routine labs in all adults with suspected or confirmed Non-Alcoholic Fatty Liver Disease (NAFLD) 1, 2
• The EASL suggests proceeding to FibroScan when FIB-4 is ≥1.3 (or ≥2.0 in patients aged ≥65 years) to identify patients requiring hepatology referral 1, 2
• FibroScan cutoff >7.0 kPa identifies significant fibrosis (≥F2) requiring closer monitoring, as recommended by The Lancet Gastroenterology and Hepatology 3, 2
• The American Association for the Study of Liver Diseases (AASLD) recommends using APRI score >0.5 or FibroScan >7.0 kPa to identify significant fibrosis (≥F2) requiring antiviral treatment in patients with chronic viral hepatitis B or C 5, 3, 2

Risk Stratification Pathway for Primary Care

• The EASL recommends an algorithmic approach for risk stratification, including identifying risk factors, checking baseline labs, and calculating FIB-4 score 1
• The EASL suggests referring patients to hepatology regardless of FibroScan results if FIB-4 score is >2.67 2

Critical Technical Validity Requirements

• A FibroScan result is only reliable when ALL three criteria are met: ≥10 successful measurements obtained, success rate ≥60%, and interquartile range <30% of median value, as stated by Praxis Medical Insights 2, 6

Interpretation Thresholds for Clinical Decision-Making

• The EASL recommends using FibroScan cutoffs of >7.0 kPa for significant fibrosis (≥F2) and >12.5 kPa for cirrhosis (F4) in patients with chronic hepatitis B or C 5, 3, 2
• The AASLD suggests using FibroScan cutoffs of <8.0 kPa to exclude advanced fibrosis and 8.2 kPa as the optimal cutoff for detecting ≥F2 in patients with NAFLD 2, 4

Patient Preparation Requirements

• The EASL recommends fasting for at least 4 hours before examination and lying supine with right arm raised in maximal abduction 2

Common Pitfalls to Avoid

• The EASL advises against relying on FibroScan alone to rule out other causes of liver disease and ensuring comprehensive etiologic workup is performed before or in parallel with FibroScan 1, 2

Follow-Up Monitoring Intervals

• The EASLD recommends repeat FibroScan every 2-3 years for patients with mild fibrosis (F0-F1) and annual monitoring with hepatology co-management for patients with advanced fibrosis or cirrhosis 6

Prognostic Value Beyond Staging

• The World Health Organization (WHO) Guideline Development Group concluded that benefits of non-invasive testing, including increased treatment availability and reduced need for liver biopsy, outweigh potential harms of false-positive results and unnecessary treatment 7, 5